AI assistant
Sending…
Ernexa Therapeutics Inc. — Director's Dealing 2021
May 5, 2021
35259_dirs_2021-05-05_c6c1ebff-e256-4698-a1d9-9d2061bf44ad.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-05-01
Reporting Person: LANGER DENNIS (N/A)
More from Ernexa Therapeutics Inc.
Major Shareholding Notification
2026
May 14
Annual Report
2026
May 11
Proxy Solicitation & Information Statement
2026
May 11
Proxy Solicitation & Information Statement
2026
May 11
Interim / Quarterly Report
2026
May 11
Share Issue/Capital Change
2026
May 4
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 1
Regulatory Filings
2026
Mar 31
Capital/Financing Update
2026
Mar 24